Loading stock data…
EVGN
$0.77-0.01 (-1.79%)
Market ClosedLast close May 1
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Evogene Ltd. in the Healthcare sector is trading at $0.77. The stock is currently near its 52-week low of $0.72, remaining 29.1% below its 200-day moving average. Technical signals show neutral RSI of 37 and bearish MACD signal, explaining why EVGN maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 37) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.77
Potential Upside
5%
Whystock Fair Value$0.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engage...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.80M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
10347.56%
Volume
Today's trading volume
64,130
Recent News
Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline
Despite a drop in revenue, Evogene Ltd (EVGN) focuses on AI-driven innovations and strategic partnerships to enhance future growth prospects.
Evogene Ltd. Q4 2025 Earnings Call Summary
Moby summary of Evogene Ltd.'s Q4 2025 earnings call
Evogene: Q4 Earnings Snapshot
REHOVOT, Israel (AP) — Evogene Ltd. (EVGN) on Thursday reported a loss of $5.3 million in its fourth quarter. On a per-share basis, the Rehovot, Israel-based company said it had a loss of 61 cents. The agricultural company posted revenue of $314,000 in the period.
Evogene: Q3 Earnings Snapshot
REHOVOT, Israel (AP) — Evogene Ltd. (EVGN) on Thursday reported profit of $3.9 million in its third quarter. The Rehovot, Israel-based company said it had profit of 44 cents per share. Losses, adjusted to account for discontinued operations, came to 31 cents per share.
Evogene Declares The Sale Of Lavie Bio’s Activity To ICL Completed
ICL Group Ltd (NYSE:ICL) is among the 13 Best Magnesium Stocks to Invest in Now. Evogene Ltd. announced the successful sale of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd (NYSE:ICL). The acquisition, which was first revealed on April 21, 2025, comprises Lavie Bio’s patented Biology Driven Design technology platform, microbial bank, pipeline […]